Predictive value of 99 mTc-labelled MAA scintigraphy for 90 Y-microspheres distribution in radioembolization treatment with resin microspheres in primary and secondary hepatic tumors
暂无分享,去创建一个
A. Haug | P. Bartenstein | M. Hacker | T. Jakobs | W. Fendler | H. Ilhan | P. Paprottka | A. Todica | A. Goritschan | P. Bartenstein
[1] R. Dhanasekaran,et al. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study , 2017, American journal of clinical oncology.
[2] A. Haug,et al. Systematic Evaluation of Tumoral 99mTc-MAA Uptake Using SPECT and SPECT/CT in 502 Patients Before 90Y Radioembolization , 2015, The Journal of Nuclear Medicine.
[3] N. Obuchowski,et al. Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post-Radioembolization 90Y PET , 2014, Front. Oncol..
[4] E. Van Cutsem,et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] F. Orsi,et al. Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective , 2014, Front. Oncol..
[6] A. Haug,et al. Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors , 2013, Oncology.
[7] T. W. Barber,et al. Comparison of positron emission tomography/CT and bremsstrahlung imaging following Y‐90 radiation synovectomy , 2013, Journal of medical imaging and radiation oncology.
[8] Marnix G E H Lam,et al. 99mTc-Macroaggregated Albumin Poorly Predicts the Intrahepatic Distribution of 90Y Resin Microspheres in Hepatic Radioembolization , 2013, The Journal of Nuclear Medicine.
[9] H. Amthauer,et al. Predictive Value of Intratumoral 99mTc-Macroaggregated Albumin Uptake in Patients with Colorectal Liver Metastases Scheduled for Radioembolization with 90Y-Microspheres , 2013, The Journal of Nuclear Medicine.
[10] C. Verslype,et al. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] E. Baudin,et al. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.
[12] H. Biersack,et al. Significance of Oral Administration of Sodium Perchlorate in Planning Liver-Directed Radioembolization , 2011, The Journal of Nuclear Medicine.
[13] F. Forrer,et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[14] A. Haug,et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[15] P. Flamen,et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres , 2008, Physics in medicine and biology.
[16] M. Burton,et al. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. , 2001, Physics in medicine and biology.
[17] M. Burton,et al. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. , 2000, Physics in medicine and biology.
[18] A. Li,et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours , 1996, European Journal of Nuclear Medicine.